Salma Jalal, Market Development Manager at Refeyn, looks at the need for and challenges of measuring antibody aggregation and discusses the ideal requirements of analytical tools to support it.  Antibody therapies have cemented their place in modern healthcare, offering powerful, targeted treatments for cancers, autoimmune disorders, infectious diseases and beyond. As advancements in R&D and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!